Professor Bradley is internationally recognized as a pioneer in developing the techniques, technology and tools for genetic manipulation in the mouse over more than 3 decades. He served as Director of the Welcome Trust Sanger Institute from 2000 to 2010. He was honored by election to the fellowship of the Royal Society in 2002. Among many projects that Dr. Bradley has established and led, is the international project to systematically knockout all genes in the mouse genome, the most ambitious use of ES-cell technology ever attempted. Over the last 30 years, Dr. Bradley has authored more than 280 publications. In his lecture, Dr. Bradley will be describing the scientific history and the technology behind the creation of the Kymouse strains which are transgenic for the total human immunoglobulin gene diversity. The platform provides a valuable means to isolate therapeutic monoclonal antibodies. Kymab has also developed single B cell-based methods to capture both the heavy and light chains of antibodies at scale. Combined with deep sequencing of millions of B cells we are able to build networks of histories of B cell families which we use to isolate rare antibodies with unique properties. The combined use of Kymouse with B cell network analysis, facilitates vaccine antigen discovery and predictive pre-clinical assessment of candidate vaccine antigens prior to clinical trials in humans.
